ArticleFrontiers in immunology2026
L-fucose administration ameliorates chronic social defeat stress-induced depressive-like behaviors by restoring GDP-fucose biosynthetic activation and core fucosylation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic psychosocial stress is a major driver of depression, yet the glycometabolic mechanisms linking stress exposure to neuroinflammation and synaptic dysfunction remain poorly understood. Here, using a chronic social defeat stress (CSDS) model, we demonstrated that L-fucose supplementation markedly attenuated depressive-like behaviors and suppressed neuroinflammation in the hippocampus. L-fucose also reduced Iba1-positive microglial accumulation, inhibited JAK2/STAT3 inflammatory signaling, and restored the stress-induced loss of synaptic proteins, including α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunits and postsynaptic density protein 95 (PSD95). Mechanistically, CSDS downregulated hippocampal guanosine 5'-diphosphate (GDP)-fucose levels, thereby impairing core fucosylation. This defect was associated with downregulation of key enzymes in the GDP-fucose salvage biosynthetic pathway, including fucokinase (FUK) and fucose-1-phosphate guanylyltransferase (FPGT), both of which were restored by L-fucose administration. Consistently, pharmacological inhibition of fucosylation with 2-fluorofucose (2FF) suppressed GDP-fucose and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.